К содержанию
Dr. Tara EinullaevaMedical oncologist

Treatment 9 min

Metastatic bladder cancer: how it is treated today

Muscle-invasive vs non-invasive bladder cancer, why chemo comes before cystectomy, what changed in first-line metastatic treatment and who needs FGFR testing.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 16 October 2026

In metastatic bladder cancer, the first-line standard has changed in recent years: instead of chemotherapy alone, the preferred option today is a combination of the antibody-drug conjugate enfortumab vedotin with the immunotherapy drug pembrolizumab. If this is not possible, platinum chemotherapy is used — followed by maintenance immunotherapy or together with it. In addition, the tumor should be tested for changes in the FGFR genes — this keeps another line of treatment in reserve.

Non-muscle-invasive or muscle-invasive: why this matters most

Bladder cancer is divided into two large groups, and the whole treatment approach depends on which one you are in.

  • Non-muscle-invasive (stages Ta, Tis, T1) — the tumor has not grown into the muscle layer of the bladder wall. Most patients fall into this group. They are treated with transurethral resection (removing the tumor through the urethra), often with BCG or chemotherapy drugs instilled into the bladder, and regular cystoscopy.
  • Muscle-invasive (T2 and above) — the tumor has grown into the muscle. Here surgery or radiotherapy with chemotherapy is needed, and systemic drug treatment becomes an essential part of the plan.

The line between these groups determines whether a patient needs a medical oncologist from the very start. In muscle-invasive cancer, drug treatment is discussed before surgery, not after it: if you go straight to surgery, the chance of chemotherapy before it will be lost.

This article is about muscle-invasive and metastatic cancer. The stage is determined from the pathology report after resection and from CT; I explained how to read such reports in my article on pathology reports.

Muscle-invasive cancer: chemotherapy before cystectomy

The standard for those who can have cisplatin is neoadjuvant cisplatin-based chemotherapy, followed by radical cystectomy (removal of the bladder with creation of a urinary diversion). According to the American Cancer Society, chemotherapy before surgery helps people live longer than surgery alone.

Another option that has appeared in the guidelines is perioperative immunotherapy with durvalumab: it is added to cisplatin chemotherapy before surgery and continued on its own afterwards.

After cystectomy, the team decides whether further treatment is needed. If the pathology of the removed bladder shows a high risk of recurrence, one option is adjuvant immunotherapy with nivolumab. Adjuvant chemotherapy (if it was not given before surgery) or radiotherapy is sometimes discussed.

For those who cannot have cisplatin, the American Cancer Society lists options with pembrolizumab and enfortumab vedotin before and after surgery, or cystectomy without prior treatment. For some patients, an alternative to surgery is bladder preservation: maximal resection of the tumor followed by chemoradiotherapy.

Who can have cisplatin

Cisplatin is a cornerstone drug in bladder cancer, but it is not suitable for everyone. Under consensus criteria (Galsky et al.), a patient is considered unfit for cisplatin if at least one of the following applies:

Criterion Value
Kidney function Creatinine clearance below 60 mL/min
Hearing Grade 2 or higher hearing loss
Nerves Grade 2 or higher neuropathy
General condition ECOG 2 (up and about more than half the day, but unable to work)
Heart NYHA class III heart failure

Pay attention to how exactly the creatinine clearance was calculated: the result depends on the formula, age and weight. If you have been told you can’t have cisplatin because of your kidneys, it makes sense to ask what the value was and how it was calculated.

Metastatic cancer: what is used first line now

Enfortumab vedotin + pembrolizumab. In 2024, ESMO named this combination the new first-line standard for advanced urothelial cancer. Enfortumab vedotin is an antibody-drug conjugate: the antibody finds a protein on the tumor cell and delivers a cytotoxic drug to it. Pembrolizumab is a PD-1 inhibitor, a form of immunotherapy.

In the EV-302 trial (886 patients), the combination was compared with platinum chemotherapy:

Measure Enfortumab vedotin + pembrolizumab Chemotherapy
Median progression-free survival 12.5 months 6.3 months
Median overall survival 31.5 months 16.1 months
Grade 3 or higher side effects 55.9% 69.5%

The side-effect profile is different from chemotherapy: among the serious ones, skin rash and raised blood sugar were more common. That is why skin and glucose are monitored during treatment, and any new rash is reported to the doctor straight away.

There is a flip side. Because of side effects, treatment was stopped more often in the combination group — in 35.0% of patients versus 18.5% on chemotherapy. This is not a reason to turn down the regimen, but it is a reason to agree with your doctor in advance on how quickly you report symptoms and who adjusts the doses. Often a side effect noticed in time allows a pause or a dose reduction rather than stopping treatment altogether.

If the combination is not possible, ESMO names alternatives: nivolumab together with cisplatin and gemcitabine, or platinum chemotherapy followed by maintenance therapy with avelumab.

The logic of the second regimen is this. The patient receives 4–6 cycles of gemcitabine with cisplatin or carboplatin. If the disease has not progressed (the tumor has shrunk or is stable), avelumab — a PD-L1 inhibitor — is started as maintenance treatment. In the JAVELIN Bladder 100 trial, median overall survival was 21.4 months with avelumab versus 14.3 months without it. I explained in detail how immunotherapy works and what its side effects are in my article on immunotherapy.

The response to avelumab can be very deep. In my clinical case of bladder cancer, I described a complete metabolic response on maintenance avelumab.

FGFR testing: why to think about it early

According to the AACR, changes in the FGFR genes are found in about 30% of bladder cancers. For patients with FGFR3 alterations, there is a targeted drug — erdafitinib (tablets). In January 2024, the FDA granted it full approval for advanced urothelial cancer with FGFR3 alterations after at least one line of systemic treatment, including a PD-1 or PD-L1 inhibitor if appropriate. In the THOR trial, median overall survival was 12.1 months on erdafitinib versus 7.8 months on chemotherapy.

The test is done on tumor tissue — material from resection or cystectomy. I advise discussing it during first-line treatment, so that the result is already available when the next treatment is needed, rather than waiting several weeks for it then.

What monitoring looks like

During treatment, the response is usually assessed by CT, sometimes by PET-CT, after several cycles. Blood tests are done before each infusion: a full blood count, creatinine, liver function tests, glucose, and thyroid hormones during immunotherapy. The exact list and schedule are set by your treating doctor.

After cystectomy, follow-up includes regular CT scans, blood tests and monitoring of the urinary diversion and kidney function. If the bladder has been preserved, regular cystoscopies are added.

Call your oncologist the same day if you have a fever, a new rash or blisters on the skin, severe thirst and frequent urination (signs of high blood sugar), diarrhea or new shortness of breath. Call your local emergency number (911 in the US, 999 in the UK, 112 in the EU) for shortness of breath at rest, confusion, a sharp drop in urine output or no urine at all, or heavy blood in the urine with clots.

Questions to ask your doctor

  • Am I fit for cisplatin? If not — by which criterion?
  • Is enfortumab vedotin with pembrolizumab being considered for me? If not — why?
  • If chemotherapy is chosen: is maintenance avelumab planned afterwards?
  • Has an FGFR test been done? If not — what material can it be done on now?
  • How and when will the response be assessed?
  • Which side effects need a same-day call?

If you have been offered a treatment plan and want to make sure it matches current guidelines, I’ll review your documents and give a second opinion. I wrote about how to prepare for such a consultation in my article on getting a second opinion from an oncologist.

Sources

  1. Treatment of Bladder Cancer, by Stage — American Cancer Society, accessed 2026
  2. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma — ESMO, Annals of Oncology, 2024
  3. Previously Untreated Advanced Urothelial Cancer: Antibody-Drug Conjugate Plus PD-1 Inhibitor — The ASCO Post (EV-302, NEJM), 2024
  4. Maintenance Avelumab Improves Survival in Advanced Bladder Cancer — The ASCO Post (JAVELIN Bladder 100), 2020
  5. Erdafitinib Granted Full Approval for Bladder Cancer — AACR, 2024
  6. Options for Cisplatin-ineligible Patients with Muscle-invasive Localized Urothelial Carcinoma — UroToday, accessed 2026

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.